<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03430037</url>
  </required_header>
  <id_info>
    <org_study_id>17-000472</org_study_id>
    <nct_id>NCT03430037</nct_id>
  </id_info>
  <brief_title>Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women</brief_title>
  <acronym>AFFIRM</acronym>
  <official_title>AFFIRM: A Phase 2 Randomized, Placebo-Controlled Study of Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to evaluate whether targeting inflammation will help reduce markers of&#xD;
      insulin resistance inflammation, bone resorption and physical dysfunction in elderly women&#xD;
      with gait disturbance. Positive results of this study would lead to the development of a&#xD;
      larger clinical trial examining the effects of this intervention on age-related dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To the researchers' knowledge, there are no published studies utilizing Fisetin in alteration&#xD;
      of frailty markers. Several studies involve use of Fisetin for its anti-oxidative and&#xD;
      anti-apoptotic effects in animal models. Fisetin may reduce oxidative stress, alleviate&#xD;
      hyperglycemia, and improve kidney function. No one has evaluated the biologic markers of&#xD;
      inflammation and frailty in older postmenopausal women. The researchers plan to evaluate&#xD;
      markers of frailty and markers of inflammation, insulin resistance, and bone resorption while&#xD;
      maintaining bone formation in older postmenopausal women.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improved 6 minute walk</measure>
    <time_frame>One Month</time_frame>
    <description>Improved gait speed</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Frail Elderly Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fisetin 20/mg/kg/day, orally for 2 consecutive days, for 2 consecutive months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules orally for 2 consecutive days, for 2 consecutive months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fisetin</intervention_name>
    <description>Flavonoid Family</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Healthy postmenopausal women&#xD;
&#xD;
          -  Age â‰¥ 70 years&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Abnormality in any of the screening laboratory studies (see below)&#xD;
&#xD;
          -  Presence of significant liver or renal disease&#xD;
&#xD;
          -  Malignancy (including myeloma)&#xD;
&#xD;
          -  Malabsorption&#xD;
&#xD;
          -  Hypoparathyroidism&#xD;
&#xD;
          -  Hyperparathyroidism&#xD;
&#xD;
          -  Acromegaly&#xD;
&#xD;
          -  Cushing's syndrome&#xD;
&#xD;
          -  Hypopituitarism&#xD;
&#xD;
          -  Gastric bypass/reduction&#xD;
&#xD;
          -  Malabsorption issues&#xD;
&#xD;
          -  Crohn's&#xD;
&#xD;
          -  Myopathies (increased or low calcium, vitamin D deficiency, elevated creatine kinase&#xD;
             or ESR)&#xD;
&#xD;
          -  If diabetic AND on sulfonylureas (like glipizide, glimepiride, glyburide), SGLT2&#xD;
             inhibitors (like dapagliflozin and empagliflozin), or insulin&#xD;
&#xD;
          -  Undergoing treatment with any medications that affect bone turnover, including the&#xD;
             following:&#xD;
&#xD;
               -  adrenocorticosteroids (&gt; 3 months at any time or &gt; 10 days within the previous&#xD;
                  yr), anticonvulsant therapy (within the previous year),&#xD;
&#xD;
               -  pharmacological doses of thyroid hormone (causing decline of thyroid stimulating&#xD;
                  hormone below normal),&#xD;
&#xD;
               -  calcium supplementation of &gt; 1200 mg/d (within the preceding 3 months),&#xD;
&#xD;
               -  bisphosphonates (within the past 3 yrs),&#xD;
&#xD;
               -  denosumab,&#xD;
&#xD;
               -  estrogen (E) therapy or treatment with a selective E receptor modulator, or&#xD;
                  teriparatide (within the past yr).&#xD;
&#xD;
          -  Subjects with a fracture within the past year&#xD;
&#xD;
          -  Subjects taking potentially senolytic agents within the last year: Fisetin, Quercetin,&#xD;
             Luteolin, Dasatinib, Piperlongumine, or Navitoclax&#xD;
&#xD;
          -  Subjects currently taking drugs that induce cellular senescence: alkylating agents,&#xD;
             anthracyclines, platins, other chemotherapy&#xD;
&#xD;
          -  QTc &gt;450 msec&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Total bilirubin &gt;2X upper limit&#xD;
&#xD;
          -  Inability to tolerate oral medication&#xD;
&#xD;
          -  eGFR &lt; 15 ml/ min/ 1.73 m2&#xD;
&#xD;
          -  Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low&#xD;
             molecular weight heparin, factor Xa inhibitors, etc.)&#xD;
&#xD;
          -  Subjects taking the following antimicrobial agents: Aminoglycosides, Azole antifungals&#xD;
             (fluconazole, miconazole, voriconazole, itraconazole), Macrolides (clarithromycin,&#xD;
             erythromycin), Antivirals (nelfinavir, indinavir, saquinavir, ritonavir,&#xD;
             elbasvir/grazoprevir), Rifampin&#xD;
&#xD;
          -  Subjects taking proton pump inhibitors who are unable or unwilling to reduce or hold&#xD;
             therapy prior to and during the 2-day Fisetin dosing&#xD;
&#xD;
          -  Subjects taking the following other drugs if they cannot be held for at least 2 days&#xD;
             before and during administration of Fisetin: digoxin, lithium, all statins,&#xD;
             repaglidine, bosentan, gemfibrozil, olmesartan, enalapril, valsartan, methotrexate,&#xD;
             corticosteroids, thyroid hormones, eluxadoline, eltrombopag, nitroglycerin,&#xD;
             pioglitazone, glyburide, enzalutamide, ezetimibe, colchicine, imatinib, cyclosporine,&#xD;
             tacolimus, sirolimus, carbamazepine, flecainide, phenytoin, phenobarbital, rifampicin,&#xD;
             theophylline, warfarin, heparin, full dose ASA, clopidogrel, celecoxib, desipramine,&#xD;
             thioridazine, venlafaxine, tizanidine, atomoxetine, voriconazole, citalopram,&#xD;
             diazepam, escitalopram, propranolol, clozapine, cyclobenzaprine, mexiletine,&#xD;
             olanzapine, ondansetron, riluzole&#xD;
&#xD;
          -  In order to ensure vitamin D sufficiency, we will also exclude subjects with serum&#xD;
             25-hydroxyvitamin D levels of &lt; 20 ng/ml.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James L Kirkland, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sundeep Khosla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tamara K Evans</last_name>
    <phone>507-284-1004</phone>
    <email>evans.tamara@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara K Evans</last_name>
      <phone>507-284-1004</phone>
      <email>evans.tamara@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>James Kirkland, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sundeep Khosla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2018</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>James L. Kirkland, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Frailty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Frailty</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

